Myocardial fibrosis in stroke survivors
| Autor: | K Y K Wong, Victoria Allgar, S. Sze, Allan D. Struthers, S. McSwiggan, S. Wong, Ronald S. MacWalter |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Male
medicine.medical_specialty Cardiomyopathy QT interval Sudden cardiac death chemistry.chemical_compound N-terminal telopeptide Risk Factors Internal medicine Medicine Humans cardiovascular diseases Survivors Aged business.industry Incidence medicine.disease Endomyocardial Fibrosis humanities United Kingdom Stroke Survival Rate Procollagen peptidase chemistry Heart failure cardiovascular system Cardiology Spironolactone Myocardial fibrosis Female Cardiology and Cardiovascular Medicine business |
| Zdroj: | International journal of cardiology. 187 |
| ISSN: | 1874-1754 |
| Popis: | Stroke survivors are most likely to die of cardiac death, yet few undergo comprehensive cardiac assessment to look for reversible causes. Myocardial fibrosis (MF) is not only the hallmark of cardiomyopathy, but also a substrate for sudden cardiac death, ventricular tachyarrhythmia and heart failure. Procollagen carboxyl-terminal telopeptide (PICP) was found to be a marker of MF. The relationship between PICP and cardiac abnormalities in stroke survivors is unknown. We recently showed that MF in stroke survivors can be treated by spironolactone and amiloride in a randomised placebo-controlled cross-over study with reduction in PICP levels and QTc [1]. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect